TherapeuticsMD (TXMD) Cash & Equivalents: 2010-2025
Historic Cash & Equivalents for TherapeuticsMD (TXMD) over the last 11 years, with Sep 2025 value amounting to $7.1 million.
- TherapeuticsMD's Cash & Equivalents rose 40.97% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.1 million, marking a year-over-year increase of 40.97%. This contributed to the annual value of $5.1 million for FY2024, which is 16.92% up from last year.
- TherapeuticsMD's Cash & Equivalents amounted to $7.1 million in Q3 2025, which was up 17.24% from $6.1 million recorded in Q2 2025.
- TherapeuticsMD's Cash & Equivalents' 5-year high stood at $137.6 million during Q1 2021, with a 5-year trough of $4.3 million in Q4 2023.
- Moreover, its 3-year median value for Cash & Equivalents was $5.7 million (2025), whereas its average is $7.6 million.
- Per our database at Business Quant, TherapeuticsMD's Cash & Equivalents tumbled by 91.23% in 2023 and then surged by 40.97% in 2025.
- Over the past 5 years, TherapeuticsMD's Cash & Equivalents (Quarterly) stood at $64.9 million in 2021, then dropped by 24.02% to $49.3 million in 2022, then tumbled by 91.23% to $4.3 million in 2023, then increased by 16.92% to $5.1 million in 2024, then spiked by 40.97% to $7.1 million in 2025.
- Its Cash & Equivalents stands at $7.1 million for Q3 2025, versus $6.1 million for Q2 2025 and $5.7 million for Q1 2025.